What is Kiniksa Pharmaceuticals International, plc worth?
With the base-case assumptions below, a discounted cash flow model on Kiniksa Pharmaceuticals International, plc's reported free cash flow gives $58.10 per share. The share price was $95.02 on November 10, 2026, 64% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $35.71 | -62% |
| Base | 15.0% | 9.0% | $58.10 | -39% |
| Bull | 20.0% | 8.0% | $99.80 | +5% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $75.06 | $80.34 | $86.80 | $94.88 | $105.26 |
| 8.0% | $62.32 | $65.75 | $69.80 | $74.66 | $80.60 |
| 9.0% | $53.05 | $55.40 | $58.10 | $61.26 | $64.99 |
| 10.0% | $46.03 | $47.69 | $49.58 | $51.74 | $54.23 |
| 11.0% | $40.53 | $41.75 | $43.12 | $44.65 | $46.39 |
Where the presets come from
Base: years 1 to 5 grow at Kiniksa Pharmaceuticals International, plc's revenue growth rate over the last 4 fiscal years (104.8% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions